Ahluwalia et al. report findings from a multicenter phase II clinical trial of TRC105, a chimeric IgG1 endoglin-directed antibody, given with and without bevacizumab, in bevacizumab-refractory glioblastoma. TRC105 administration resulted in increased circulating VEGF-A and combined with bevacizumab resulted in a median survival of 5.7 months.
- Manmeet S. Ahluwalia
- Lisa R. Rogers
- Charles P. Theuer
